Smac Mimetics and TNFα: A Dangerous Liaison?  by Wu, Hao et al.
Leading Edge
MinireviewSmac Mimetics and TNFα:  
A Dangerous Liaison?
Hao Wu,1,* Jurg Tschopp,2 and Su-Chang Lin1
1Department of Biochemistry, Weill Medical College of Cornell University, New York, NY 10021, USA
2Department of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland
*Correspondence: haowu@med.cornell.edu
DOI 10.1016/j.cell.2007.10.042
Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 are upregulated in 
many cancer cells. It has been thought that small-molecule mimetics of Smac, an endog-
enous IAP antagonist, might potentiate apoptosis in cancer cells by promoting caspase 
activation. However, three recent papers, two in Cell (Vince et al., 2007; Varfolomeev et 
al., 2007) and one in Cancer Cell (Petersen et al., 2007), now report that Smac mimetics 
primarily kill cancer cells via a different mechanism, the induction of autoubiquitination and 
degradation of cIAPs, which culminates in TNFα-mediated cell death.Re-establishing the apoptotic program in tumor cells 
is a much dreamed about strategy for cancer therapy. 
One possible approach involves small molecules that 
mimic the antagonistic activity of Smac (also known 
as Diablo) toward inhibitor of apoptosis proteins (IAPs) 
such as XIAP, cIAP1, and cIAP2. Smac and its synthetic 
small-molecule mimetics interact with the BIR domain 
of IAPs. Because XIAP is a bona fide caspase inhibitor, 
it was presumed that Smac mimetics primarily target 
XIAP thus allowing activation of caspase-9, result-
ing in the triggering of apoptosis. In contrast to XIAP, 
cIAP1 and cIAP2 are weak caspase inhibitors in vitro 
but associate with two tumor necrosis factor recep-
tor (TNFR) signaling proteins, TRAF1 and TRAF2, to 
participate in TNFα-induced NF-κB activation (Rothe 
et al., 1995). The goal has been to use Smac mimetics 
in combination with chemo- or radiation therapy that 
activates caspase-9 via the mitochondrial apoptotic 
pathway. In principal, this combination therapy should 
enhance cancer cell apoptosis by relieving any cas-
pase activities held in check by IAPs.
As three related papers in Cell and Cancer Cell 
now report, Smac mimetics exceed expectations as 
potentiators of cancer cell apoptosis as they induce 
cell death in multiple cancer cell lines even when used 
alone (Petersen et al., 2007; Varfolomeev et al., 2007; 
Vince et al., 2007). The three groups independently 
developed small molecules that mimic the N-terminal 
AVPI sequence of mature Smac but are different in 
their detailed chemical structures. All but one of the 
developed Smac mimetics are dimers, resembling the 
dimeric structure of Smac. As evidence that this killing 
activity is likely not due to off-target toxicity, the Smac 
mimetic used by Petersen et al. (2007) only pulled down 
its intended targets, XIAP, cIAP1, and cIAP2, and their 
associated proteins, TRAF1 and TRAF2. Surprisingly, 
cell death induced by the Smac mimetics is depen-dent on caspase-8 but not caspase-9 (Petersen et al., 
2007; Varfolomeev et al., 2007), and this cell death can 
be prevented by the caspase-8 inhibitor crmA (Vince 
et al., 2007). Because caspase-8 is the primary ini-
tiator caspase in the apoptotic pathway mediated by 
death receptors (such as Fas, TRAIL receptors, and 
TNF receptor 1), the dependence on caspase-8 is 
consistent with the earlier observed synergy between 
Smac mimetics and death receptor ligands (Li et al., 
2004). However, the molecular mechanism by which 
Smac mimetics induce caspase-8-dependent apop-
tosis is not known.
Smac Mimetics and cIAP1 Degradation
Elegant independent studies by the three groups have 
now uncovered TNFα, a death receptor ligand, as 
the major culprit in cancer cell apoptosis induced by 
Smac mimetics (Petersen et al., 2007; Varfolomeev et 
al., 2007; Vince et al., 2007). Knockdown with small-
interfering RNAs (siRNAs) of TNF receptor 1 (TNFR1) 
but not of Fas, TRAIL-R1, and TRAIL-R2 prevented 
Smac mimetic-induced apoptosis of cancer cells. 
Similarly, specific knockdown of TNFα but not FasL 
or TRAIL promoted the survival of cells treated with 
Smac mimetics (Petersen et al., 2007; Varfolomeev et 
al., 2007). Thus, the emerging model (Figure 1) is that 
in addition to targeting XIAP to relieve caspase-9 inhi-
bition in the intrinsic cell death pathway, Smac mimet-
ics target cIAPs, especially cIAP1, to stimulate their 
autoubiquitination and degradation, leading to NF-κB 
activation and TNFα secretion. The autocrine TNFα 
signaling in turn induces caspase-8 activation and 
cancer cell death.
The first dramatic effect of Smac mimetics is the 
induction of cIAP1 and cIAP2 degradation within min-
utes of treatment without affecting the levels of other 
IAPs or TRAFs (Varfolomeev et al., 2007; Vince et al., Cell 131, November 16, 2007 ©2007 Elsevier Inc. 655
Figure 1. Cancer Cell Death Induced by 
Smac Mimetics
In nonstimulated tumor cells, cIAPs bound to 
TRAF2 ubiquitinate and degrade the kinase 
NIK, thereby inhibiting the noncanonical NF-
κB pathway. The addition of Smac mimetics 
stimulates autoubiquitination of cIAPs, result-
ing in their proteasomal degradation, which in 
turn leads to the stabilization of NIK. Moreover, 
TRAF2 freed from cIAPs facilitates recruitment 
of the kinase RIP1 to tumor necrosis factor 
receptor 1 (TNFR1). These result in the activa-
tion of the noncanonical and canonical NF-κB 
pathways, causing TNFα production in a sub-
stantial number of tumor cells. Smac mimet-
ics also lead to sensitivity to TNFα-induced 
cell death, likely through the degradation of 
cIAPs, which are inhibitors of apoptosis, and 
by favoring the formation of a RIP1-dependent 
caspase-8-activating complex.2007). The degradation of cIAP1 and cIAP2 is depen-
dent on the concentration of the Smac mimetic, with 
cIAP1 degradation occurring at a much lower con-
centration than cIAP2. Because cIAPs are ubiquitin 
ligases capable of autoubiquitination and ubiquitina-
tion of several binding proteins, it was suspected that 
their degradation might depend on the proteasome. 
Indeed, the proteasome inhibitor MG132 prevented 
the loss of cIAP1 and cIAP2 induced by the Smac 
mimetics (Varfolomeev et al., 2007; Vince et al., 2007). 
In contrast, the pan-caspase inhibitor z-VAD did not 
have any effect on cIAP1 and cIAP2 degradation. For 
Smac mimetic-induced degradation to occur, the IAP 
proteins require both a functional RING domain and 
an intact interaction site for a Smac mimetic. Further-
more, in vitro reconstitution of the autoubiquitination 
reaction using purified E1, E2 (UbcH5a), and cIAP1 
showed that Smac mimetics quickly and markedly 
enhanced autoubiquitination of cIAP1 (Varfolomeev et 
al., 2007).
How Smac mimetics stimulate cIAP1 autoubiquit-
ination remains unclear. Although a bivalent Smac 
mimetic induces dimerization of the cIAP1 BIR2-
BIR3 domain in vitro, this dimerization is not a pre-
requisite for cIAP1 ubiquitination and degradation, 
as the monovalent Smac mimetic is equally effective 
at similar concentrations (Varfolomeev et al., 2007). 
Another possibility is offered by the fact that many 
ubiquitin ligases stimulate their own ubiquitination in 
the absence of their substrates. However, the Smac 
mimetics did not dissociate cIAPs from TRAF2, and 
hence cIAPs likely stay bound with TRAF2-associated 
ubiquitination targets (Varfolomeev et al., 2007). At the 
moment, the most plausible explanation is that Smac 
mimetics alter the protein conformation of cIAPs to 
allow better access of the Lys residues to the E2s 
bound to the RING domain.656 Cell 131, November 16, 2007 ©2007 Elsevier Inc.Activation of NF-κB Signaling Pathways
Loss of cIAPs induces activation of both the canoni-
cal and noncanonical NF-κB signaling pathways as 
manifested by IκB degradation and p100 process-
ing, respectively. Remarkably, IκB phosphorylation 
occurs within minutes of treatment of Smac mimetics, 
with kinetics that are similar to TNFα-induced NF-κB 
activation. IκB phosphorylation and degradation are 
not affected by cotreatment with Fc-TNFR1, which 
blocks TNFR1 signaling, demonstrating that receptor 
signaling is not involved in activation of the canonical 
NF-κB pathway by the Smac mimetic (Varfolomeev et 
al., 2007). An increase in the recruitment of the kinase 
RIP1 (receptor-interacting protein 1) to the TNFR1 sig-
naling complex was observed after a short treatment 
with a Smac mimetic (Vince et al., 2007). Increased 
RIP1 recruitment was also observed in cIAP1-deficient 
mouse embryonic fibroblasts (MEFs), which cannot be 
further increased by Smac mimetic treatment (Vince et 
al., 2007), suggesting that loss of cIAP1 is responsible 
for the increased recruitment of RIP1. Because RIP1 
binding to TNFR1 is known to result in NF-κB activation, 
it is argued that loss of cIAP1 leads to activation of the 
canonical NF-κB pathway via increased RIP1 recruit-
ment to TNFR1 (Vince et al., 2007). However, because 
the pulldown establishing enhanced RIP1 recruitment 
was performed with Fc-TNFα and not with an antago-
nistic antibody to TNFR1, the possibility exists that the 
increased RIP1 recruitment is dependent on TNFα, 
rather than a direct effect of the Smac mimetics.
The mechanism for the activation of the noncanoni-
cal NF-κB pathway by Smac mimetics is more clearly 
elucidated (Varfolomeev et al., 2007; Vince et al., 2007). 
A highly labile kinase NIK is a crucial player in this path-
way. It phosphorylates IKKα, leading to p100 phospho-
rylation and processing to p52. NIK constitutively asso-
ciates with TRAFs, such as TRAF2 and TRAF3, which 
have been shown to negatively regulate the noncanoni-
cal NF-κB pathway (He et al., 2007; Malinin et al., 1997). 
Because TRAF2 in turn forms a constitutive complex 
with cIAPs, it was hypothesized that cIAPs may be the 
ubiquitin ligase for NIK ubiquitination and responsible 
for the instability of NIK in cells. Indeed, coexpression 
of NIK with cIAP1 or cIAP2 led to disappearance of NIK 
whereas coexpression with a RING domain mutant of 
cIAP1 did not. Treatment of cells stably expressing NIK 
with a Smac mimetic triggered degradation of endoge-
nous cIAP1 and a remarkable increase of the NIK protein 
level. The Smac mimetic-induced processing of p100 
occurs with much slower kinetics than IκB phosphoryla-
tion, presumably due to the time required to synthesize 
and to accumulate NIK to a functional level. Degrada-
tion of cIAP1 and stabilization of NIK are also compo-
nents of the physiological noncanonical NF-κB pathway 
as shown by treatment with the TNF-like ligand TWEAK 
(Varfolomeev et al., 2007).
Activation of the NF-κB signaling pathway leads to the 
induction of many genes. An important effector protein 
in this case is TNFα, which is only induced in cancer cell 
lines sensitive to treatment with Smac mimetics (Varfo-
lomeev et al., 2007; Vince et al., 2007). What determines 
whether NF-κB activation induces TNFα production is 
not known. Sensitive cell lines already secrete TNFα 
before any treatment (Petersen et al., 2007), although it is 
unknown whether TNFα secretion is further increased in 
these same cell lines upon treatment with Smac mimet-
ics. It is also unclear whether only one or both of the 
canonical and noncanonical NF-κB pathways is required 
for TNFα induction. A more in-depth analysis will be 
required to clarify this point.
TNFα-Induced Cell Death
Remarkably, loss of cIAPs due to Smac mimetic treat-
ment also appears to assist TNFα-induced cell death. 
Unlike FasL, TNFα does not readily induce cell death in 
most circumstances. Rather, it activates NF-κB and MAP 
kinases, leading to cell survival and cell activation. Previ-
ous studies have shown that TNFα-induced cell death is 
accomplished via a secondary TRADD-RIP1-FADD-cas-
pase-8 complex devoid of TNFR1 (Micheau and Tschopp, 
2003). In keeping with this notion, RIP1 is also required 
for cell death induced by a Smac mimetic, even in the 
presence of exogenous TNFα for both sensitive cancer 
cell lines and those that are resistant to Smac mimetics 
alone but do respond to costimulation by TNFα (Petersen 
et al., 2007). In contrast, knockdown of the adaptor pro-
tein TRADD modestly increases apoptosis (Petersen et 
al., 2007). Immunoprecipitation of caspase-8 after Smac 
mimetic treatment revealed the formation of a RIP1-
FADD-caspase-8 complex that did not contain TRADD 
or TRAF2 (Petersen et al., 2007). The lack of TRADD and 
TRAF2 in the death signaling complex is interesting as it 
is different from the classical view in which TRADD serves 
as the central platform molecule for the recruitment of 
both TRAF2 and FADD.Is it possible that cancer cells respond to TNFα differ-
ently? In fact, a recent report also showed that RIP1 is 
crucial in TNFα-induced cell apoptosis in human tumor 
cells (Jin and El-Deiry, 2006). RIP1 was first cloned as 
a Fas-interacting protein that induces apoptosis upon 
overexpression (Stanger et al., 1995) and was also 
shown to be essential for FasL-mediated necrotic cell 
death (Holler et al., 2000). However, RIP1 knockout cells 
are defective in TNFα-induced NF-κB activation (Kelliher 
et al., 1998). The apparent involvement of RIP1 in both 
apoptosis and activation of NF-κB is consistent with 
RIP1 as both a protein required for survival and a protein 
that can induce cell death when overexpressed.
Resistance versus Sensitivity to Smac Mimetics
The studies collectively reveal that there may be three 
different kinds of cancer cells defined by their resis-
tance and sensitivity to Smac mimetics. The first type 
would be those that are sensitive to Smac mimetics 
as single agents. In this type of cells, Smac mimetics 
induce or perhaps enhance TNFα synthesis and secre-
tion and render the cells sensitive to TNFα-induced 
apoptosis by forming a RIP1-dependent caspase-8-
activating complex. The second type of cancer cells 
would be those that do not respond to Smac mimetic 
treatment alone but are sensitive to Smac mimetics 
when costimulated by exogenous TNFα. In these cells, 
treatment with a Smac mimetic fails to induce TNFα 
secretion but sensitizes the cells to apoptosis induced 
by several death receptors. The precise mechanism 
for this pro-death activity is not known. In fact, the 
increase in NF-κB activity seen in cells treated with 
Smac mimetics would suggest that the contrary is 
more prevalent. However, it is likely that apart from 
NF-κB, other signaling pathways such as JNK are 
activated to lead to the degradation of the antiapop-
totic protein cFLIP (Chang et al., 2006). There may be 
a third category of cancer cells that are resistant to 
cotreatment with Smac mimetics and TNFα. These 
cells do not form a RIP1-dependent caspase-8-acti-
vating complex upon the cotreatment. It is interesting 
that Smac mimetics induced degradation of cIAPs in 
all cell lines tested (Varfolomeev et al., 2007), suggest-
ing that additional switch points control the sensitivity 
to Smac mimetics.
Conclusion
The role of Smac mimetics in cancer cells appears to 
be 2-fold (Figure 1). First, they stimulate autoubiquitina-
tion of cIAPs, resulting in their proteasomal degradation. 
This in turn leads to NIK stabilization and facilitates RIP1 
recruitment. This results in the activation of the nonca-
nonical and canonical NF-κB pathways, causing TNFα 
production in a substantial number of tumor cells. Sec-
ond, Smac mimetics lead to sensitivity to TNFα-induced 
cell death, likely through the degradation of cIAPs and 
by favoring the formation of a RIP1-dependent caspase-
8-activating complex. Further boosting the potential of Cell 131, November 16, 2007 ©2007 Elsevier Inc. 657
Smac mimetics for clinical use, Petersen et al., (2007) 
showed that cancer cells that are sensitive to Smac 
mimetic treatment in vitro are also responsive to the 
same treatment in an in vivo mouse model.
One might argue, however, that cIAPs are also pres-
ent in nontransformed cells and that Smac mimetics 
will be potentially toxic considering the rapid degrada-
tion of cIAP1 and activation of NF-κB in primary MEFs 
upon Smac mimetic treatment (Vince et al., 2007). Yet, 
Smac mimetics do not kill nontransformed cells even 
though increased RIP1 recruitment is observed. More-
over, cIAP1 knockout mice appear normal with respect 
to TNFα-mediated NF-κB activation and cell death, 
indicating a high selectivity for tumor cells. It has been 
known for many years that cell transformation shifts the 
balance in death receptor signaling pathways from pro-
survival to pro-cell death. For example, TRAIL and FasL 
preferentially kill transformed cells and spare most pri-
mary cells. Although the molecular reason for this differ-
ence in sensitivity is still poorly understood, this gap in 
our knowledge does not impede the clinical trials that are 
ongoing with both of the TNF ligand family members.
Ironically, TNFα was the first member of this family to 
be considered as an antitumor drug. However, despite 
incredible expectations, the use of TNFα in the treat-
ment of cancer patients turned out to be limited to limb 
perfusion due to TNFα’s toxic proinflammatory activ-
ity when administered systemically. This may be set to 
change with the arrival of Smac mimetics that trigger 
an increase in TNFα production at a barely detectable 
and nontoxic level.658 Cell 131, November 16, 2007 ©2007 Elsevier Inc.ReFeReNCeS
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